Synairgen plc (LON:SNG)‘s stock had its “corporate” rating reiterated by stock analysts at FinnCap in a research report issued to clients and investors on Thursday. They currently have a GBX 137 ($1.79) target price on the stock. FinnCap’s price target indicates a potential upside of 291.43% from the stock’s current price.

Shares of Synairgen plc (LON:SNG) opened at 35.00 on Thursday. The company has a 50 day moving average price of GBX 34.15 and a 200 day moving average price of GBX 30.05. The company’s market cap is GBX 31.96 million. Synairgen plc has a one year low of GBX 19.00 and a one year high of GBX 38.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Synairgen plc Company Profile

Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls).

Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with's FREE daily email newsletter.